Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine

Robert A. Kyle, Philip R. Greipp, John P. Garton, Morie Gertz

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

This is the first prospectively randomized study of the use of melphalan/prednisone and colchicine in the treatment of primary systemic amyloidosis. One hundred one patients were stratified according to their dominant clinical manifestation. Forty-nine patients initially received melphalan/prednisone and eight subsequently had colchicine added to their regimen. Fifty-two patients initially received colchicine and 35 subsequently required melphalan/prednisone because of progressive disease. There was no difference in survival when the two groups were analyzed in aggregate (melphalan/prednisone, 25.2 months versus colchicine, 18 months; p = 0.23). When the survival of patients receiving only one regimen was analyzed or when survival was analyzed from the time of entry into the study to the time of death or progression of disease, significant differences (p <0.001 and p <0.0001, respectively) were evident, favoring melphalan/prednisone. This study suggests that melphalan/prednisone is superior to colchicine in the treatment of primary amyloidosis, but to confirm this impression, a study without a crossover group is necessary.

Original languageEnglish (US)
Pages (from-to)708-716
Number of pages9
JournalThe American journal of medicine
Volume79
Issue number6
DOIs
StatePublished - Jan 1 1985

Fingerprint

Melphalan
Colchicine
Prednisone
Survival
Disease Progression
Primary amyloidosis
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. / Kyle, Robert A.; Greipp, Philip R.; Garton, John P.; Gertz, Morie.

In: The American journal of medicine, Vol. 79, No. 6, 01.01.1985, p. 708-716.

Research output: Contribution to journalArticle

Kyle, Robert A. ; Greipp, Philip R. ; Garton, John P. ; Gertz, Morie. / Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. In: The American journal of medicine. 1985 ; Vol. 79, No. 6. pp. 708-716.
@article{ead4b531232a4e3ab1bf99d646eec353,
title = "Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine",
abstract = "This is the first prospectively randomized study of the use of melphalan/prednisone and colchicine in the treatment of primary systemic amyloidosis. One hundred one patients were stratified according to their dominant clinical manifestation. Forty-nine patients initially received melphalan/prednisone and eight subsequently had colchicine added to their regimen. Fifty-two patients initially received colchicine and 35 subsequently required melphalan/prednisone because of progressive disease. There was no difference in survival when the two groups were analyzed in aggregate (melphalan/prednisone, 25.2 months versus colchicine, 18 months; p = 0.23). When the survival of patients receiving only one regimen was analyzed or when survival was analyzed from the time of entry into the study to the time of death or progression of disease, significant differences (p <0.001 and p <0.0001, respectively) were evident, favoring melphalan/prednisone. This study suggests that melphalan/prednisone is superior to colchicine in the treatment of primary amyloidosis, but to confirm this impression, a study without a crossover group is necessary.",
author = "Kyle, {Robert A.} and Greipp, {Philip R.} and Garton, {John P.} and Morie Gertz",
year = "1985",
month = "1",
day = "1",
doi = "10.1016/0002-9343(85)90521-2",
language = "English (US)",
volume = "79",
pages = "708--716",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine

AU - Kyle, Robert A.

AU - Greipp, Philip R.

AU - Garton, John P.

AU - Gertz, Morie

PY - 1985/1/1

Y1 - 1985/1/1

N2 - This is the first prospectively randomized study of the use of melphalan/prednisone and colchicine in the treatment of primary systemic amyloidosis. One hundred one patients were stratified according to their dominant clinical manifestation. Forty-nine patients initially received melphalan/prednisone and eight subsequently had colchicine added to their regimen. Fifty-two patients initially received colchicine and 35 subsequently required melphalan/prednisone because of progressive disease. There was no difference in survival when the two groups were analyzed in aggregate (melphalan/prednisone, 25.2 months versus colchicine, 18 months; p = 0.23). When the survival of patients receiving only one regimen was analyzed or when survival was analyzed from the time of entry into the study to the time of death or progression of disease, significant differences (p <0.001 and p <0.0001, respectively) were evident, favoring melphalan/prednisone. This study suggests that melphalan/prednisone is superior to colchicine in the treatment of primary amyloidosis, but to confirm this impression, a study without a crossover group is necessary.

AB - This is the first prospectively randomized study of the use of melphalan/prednisone and colchicine in the treatment of primary systemic amyloidosis. One hundred one patients were stratified according to their dominant clinical manifestation. Forty-nine patients initially received melphalan/prednisone and eight subsequently had colchicine added to their regimen. Fifty-two patients initially received colchicine and 35 subsequently required melphalan/prednisone because of progressive disease. There was no difference in survival when the two groups were analyzed in aggregate (melphalan/prednisone, 25.2 months versus colchicine, 18 months; p = 0.23). When the survival of patients receiving only one regimen was analyzed or when survival was analyzed from the time of entry into the study to the time of death or progression of disease, significant differences (p <0.001 and p <0.0001, respectively) were evident, favoring melphalan/prednisone. This study suggests that melphalan/prednisone is superior to colchicine in the treatment of primary amyloidosis, but to confirm this impression, a study without a crossover group is necessary.

UR - http://www.scopus.com/inward/record.url?scp=0022351610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022351610&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(85)90521-2

DO - 10.1016/0002-9343(85)90521-2

M3 - Article

VL - 79

SP - 708

EP - 716

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 6

ER -